Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

06. Mai 2015 12:52 ET | Quelle: TetraLogic Pharmaceuticals

TetraLogic Announces Termination of Public Offering

MALVERN, Pa., May 6, 2015 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG), a clinical-stage biopharmaceutical company focused on discovering and developing novel small...
06. Mai 2015 10:14 ET | Quelle: TetraLogic Pharmaceuticals

TetraLogic Announces Temporary Halt of Chronic Hepatitis B Trial

MALVERN, Pa., May 6, 2015 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG), a clinical-stage biopharmaceutical company focused on discovering and developing novel small...
01. Mai 2015 08:56 ET | Quelle: TetraLogic Pharmaceuticals

TetraLogic Announces Pricing of $25 Million Public Offering

MALVERN, Pa., May 1, 2015 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG), a clinical-stage biopharmaceutical company focused on discovering and developing novel small...
30. April 2015 16:01 ET | Quelle: TetraLogic Pharmaceuticals

TetraLogic Announces Public Offering of Common Stock

MALVERN, Pa., April 30, 2015 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG), a clinical-stage biopharmaceutical company focused on discovering and developing novel small...
21. April 2015 08:00 ET | Quelle: TetraLogic Pharmaceuticals

TetraLogic Announces Publication of Two Papers Describing Birinapant's Preclinical Activity in Chronic Hepatitis B

MALVERN, Pa., April 21, 2015 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG), a clinical-stage biopharmaceutical company focused on discovering and developing novel small...
20. April 2015 08:00 ET | Quelle: TetraLogic Pharmaceuticals

TetraLogic and Merck to Collaborate on the Evaluation of Birinapant in Combination With KEYTRUDA(R) (pembrolizumab) in Solid Tumors

MALVERN, Pa. and KENILWORTH, N.J., April 20, 2015 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG), a clinical-stage biopharmaceutical company focused on discovering and...
09. April 2015 10:11 ET | Quelle: TetraLogic Pharmaceuticals

TetraLogic to Present at the 14th Annual Needham Healthcare Conference

MALVERN, Pa., April 9, 2015 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that J. Kevin Buchi, President and Chief Executive Officer, will present at the...
26. Februar 2015 16:10 ET | Quelle: TetraLogic Pharmaceuticals

TetraLogic Reports 2014 Financial Results and Provides Clinical Programs Update

MALVERN, Pa., Feb. 26, 2015 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG), a clinical-stage biopharmaceutical company focused on discovering and developing novel small...
18. Dezember 2014 07:00 ET | Quelle: TetraLogic Pharmaceuticals

TetraLogic Announces Initiation of a Randomized Phase 2 Clinical Trial of SHAPE in Subjects With Cutaneous T-Cell Lymphoma

MALVERN, Pa., Dec. 18, 2014 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced the initiation of a randomized Phase 2 clinical trial of SHAPE in subjects with...
16. Dezember 2014 07:00 ET | Quelle: TetraLogic Pharmaceuticals

TetraLogic Provides Update on Ovarian Cancer Study

MALVERN, Pa., Dec. 16, 2014 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that it intends to proceed with the expansion phase of its study in patients with...

Vorherige Seite

Nächste Seite